Decoy Therapeutics Inc.
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $0
- Net income
- -$12.5M
- Total assets
- $11.1M
- Market cap
- $3.5M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $3.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 29, 2015
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Decoy Therapeutics Inc..